Commentary on "A review of new drugs approved by the food and drug administration in 2022"

被引：0

作者：

Sharma, Kopal ^{[1
]}

Sharma, Amit ^{[2
]}

Kapadia, Rupa ^{[1
]}

机构：

[1] SMS Med Coll & Hosp, Dept Pharmacol, Jaipur 302004, Rajasthan, India

[2] Rajasthan Dent Coll, Dept Oral & Maxillofacial Surg, Jaipur, Rajasthan, India

来源：

JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE | 2024年 / 13卷 / 03期

关键词：

D O I：

10.4103/jfmpc.jfmpc_1833_23

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

引用

页码：1133 / 1133

页数：1

共 50 条

[41] FEATURES OF NEW DRUG INDICATIONS NOT APPROVED BY THE FOOD AND DRUG ADMINISTRATION, 2008-2017
Zhang, Audrey D.
Schwartz, Jason L.
Ross, Joseph S.
[J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (SUPPL 1) : S132 - S133
[42] New antimicrobial agents approved by the US Food and Drug Administration in 2001 and new indications for previously approved agents
不详
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) : 1160 - 1160
[43] New antimicrobial agents approved by the US Food and Drug Administration in 1999 and new indications for previously approved agents
不详
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) : 1114 - 1115
[44] New antimicrobial agents approved by the US Food and Drug Administration in 1998 and new indications for previously approved agents
不详
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) : 993 - 994
[45] New antimicrobial agents approved by the US food and drug administration in 2000 and new indications for previously approved agents
不详
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) : 1315 - 1315
[46] New antimicrobial agents approved by the US food and drug administration in 2005 and new indications for previously approved agents
不详
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (05) : 1912 - 1912
[47] An Analysis of Dosing-Related Postmarketing Requirements for Novel Oncology Drugs Approved by the US Food and Drug Administration, 2012-2022
Collins, Grace
McKelvey, Brittany
Andrews, Hillary S.
Allen, Jeff D.
Stewart, Mark D.
[J]. CLINICAL CANCER RESEARCH, 2024, 30 (05) : 937 - 941
[48] Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014
Pinnow, Ellen
Amr, Sania
Bentzen, Soren M.
Brajovic, Sonja
Hungerford, Laura
St George, Diane Marie
Dal Pan, Gerald
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (02) : 390 - 400
[49] Review of Evidence Supporting 2022 US Food and Drug Administration Drug Approvals
Kaplan, Robert M.
Koong, Amanda J.
Irvin, Veronica
[J]. JAMA NETWORK OPEN, 2023, 6 (08) : e2327650
[50] Risk of Enzyme- and Transporter-mediated Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2022: A Detailed Analysis of In Vitro and Clinical Data Available in New Drug Application Reviews
Yu, Jingjing
Wang, Yan
Ragueneau-Majlessi, Isabelle
[J]. CLINICAL THERAPEUTICS, 2024, 46 (06) : 499 - 508

← 1 2 3 4 5 →